Search research articles
Contact Us
Filters
Showing results (111-120 of 167) with videos related to
Page
of 17
Sort By:
Molecular Cancer Therapeutics
|
July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
Erika P Hamilton, Judy S Wang, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Mark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
British Journal of Cancer
|
September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H Voss, Michael S Gordon, Monica Mita, et al.
Blood
|
June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial
Lindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Clinical Therapeutics
|
February 29, 2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors
Gerald Falchook, Amita Patnaik, Debra L Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2023
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
Maria Vieito, Victor Moreno, Anna Spreafico, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
Investigational New Drugs
|
September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 167) with videos related to
Sort By:
Page
of 17
Molecular Cancer Therapeutics
|
July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
Erika P Hamilton, Judy S Wang, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Mark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
British Journal of Cancer
|
September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H Voss, Michael S Gordon, Monica Mita, et al.
Blood
|
June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial
Lindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Clinical Therapeutics
|
February 29, 2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors
Gerald Falchook, Amita Patnaik, Debra L Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2023
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
Maria Vieito, Victor Moreno, Anna Spreafico, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
Investigational New Drugs
|
September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Page
of 17